Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager.

Slides:

Advertisements

Similar presentations

TESTS USED IN BLOOD SCREENING French Blood Services (EFS)

Advertisements

Chagas Tests: Development and Standardization

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.

Unit 6 Diagnosis & Follow-up of HIV Infection

HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Comparison of the HIV LIA vs WB on HIV-Negative Samples CDC-HIV Diagnostics Meeting “New Diagnostic Technologies” Dec 5-7, 2007 Dr. John Kim National Laboratory.

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

WHO comparative evaluation of serologic assays for Chagas disease Journal Club April 2, 2009.

Blood Products Advisory Committee Meeting Harold S. Gaithersburg, MD December 14, 2010 Harold S. Margolis, MD Chief, Dengue Branch Centers for Disease.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Vironostika® HIV-1 Plus O Microelisa System

Enzyme-linked Immunosorbent Assay

Dengue Virus and Its Risk to the U.S. Blood Supply

Latin American Countries Map Review. Mexico Nicaragua Panama Colombia Haiti Puerto Rico Jamaica Honduras The Bahamas Cuba United States Belize Guatemala.

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

OnSite HAV IgM Rapid Test Upgraded to Revision H for Better Sensitivity CTK-MK-PPT-R0090 Rev 1.0.

Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.

HIV Testing CDC power point edited by M. Myers

El mundo español Jack Miley

Why Learn a Foreign Language?

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

Why is it important to learn Spanish?

Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa,

ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.

T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors Robert Duncan, Ph.D. DETTD, CBER, FDA Blood Products.

Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.

NextLast The Americas. NextLast The Americas The region “The Americas” encompasses North, South, Central America and the Caribbean. The region “The Americas”

1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.

Chagas Testing Icky things that can drop on you from your thatched roof! ABC 7-04.

Skilled Migration and Brain Drain from Latin America Çağlar Özden DECRG The World Bank The views expressed in this presentation are those of the author.

Proposed 10-Year Regional Plan On Oral Health Lessons learned Forty national oral health surveys indicate a marked decline between 35% to 85%

Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.

DO NOW: Identify the countries based on their shape

Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.

FLAG ICONS – 56 COUNTRIES ARGENTINA Example text. Go ahead an replace it with your own text. example text SPAIN Example text. Go ahead an replace it with.

Panbio Dengue Duo Cassette

Los países hispanohablantes The Spanish-speaking countries.

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,

PROPOSED CANDIDATE MATERIAL FOR A WHO PANEL FOR SEROLOGICAL REFERENCE RESULTS OF THE FEASIBILITY STUDIES WITH SERA FROM TC I REGION RESULTS OF THE FEASIBILITY.

PADI Division of Production, Productivity and Management Unit of Industrial and Technological Development Program for the Analysis of Industrial Dinamics.

January 27, Paul Contestable Principal Scientist Ortho Clinical Diagnostics Second WHO Consultation: Development of a WHO Reference Panel for the.

DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.

Latin American Ethnicities. Read Page 32 in the CRCT Prep Book.

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

A Comparative Analysis of EIA Systems in Latin America Ernesto Sánchez Triana and Santiago Enríquez 27th Annual Conference of IAIA Seoul, Korea 3-9 June,

E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.

Estimating Frequency of Travel to Endemic Areas Brian Custer, PhD, MPH Blood Systems Research Institute Blood Products Advisory Committee Meeting August.

 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.

BioPlex 2200 HIV Ag-Ab Assay

McClure iMovie Magic. Step One Generate 10 interests of yours, example: Civil War Create an open ended question for each interest, example: Civil War-

RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.

Proposed candidate materials and results of the feasibility studies for a WHO serological reference panel T.cruzi type II Márcia Otani Fundação Pró-Sangue.

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

Global Rapid Diagnostic Leader SD. 2 HIV-2 positive HIV-1 positive 1 drop of blood (Simple) Wait in 1~5 Min. (Fast) Interpret the result visually (Accurate)

LATIN AMERICA Introduction

Screening for Trypanosoma cruzi antibodies and Strongyloides stercoralis antibodies in migrants to Italy coming from endemic areas using four immunological.

Latin American Countries Map Review

Analysis of Performance Contracts

Maps and Capitals of Latin America and Spain

LATIN AMERICA MAP REVIEW

LATIN AMERICA Introduction

Do Now – 9/8 & 9/9 Word of the day:

Some Basic Map Geography of Latin America and the Caribbean

Challenges for Blood Donor Confirmatory Testing Algorithms

Presentation transcript:

Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager

 Abbott’s approach to Chagas Testing  PRISM Chagas  Description of the assay  Performance  Chagas Confirmatory  Description of the assay  Performance

Abbott’s Strategy in Blood Screening for Chagas Disease Develop a recombinant antigen based assay for antibodies to T. cruzi on the PRISM platform  Well-characterized antigens  Presenting multiple epitopes  Non-biohazardous Develop a recombinant antigen based Confirmatory assay for resolution of PRISM Repeat Reactive specimens.

PRISM Chagas Assay

PRISM Chagas Screening Assay Design Configuration Dual rAg Coated  P, Single mAb Conjugate, Two–Step Assay

Multi-epitope rAg Amino acidsMol. Wt. (Kda) TcF858.3 FP FP FP Multi-epitope Recombinant Antigens used in PRISM Chagas Assay

Specificity StudyTotal Repeatedly Reactive Confirmed Positive Resolved Specificity In-House Feasibility Testing 7, % Field Study4, % Total11, % Random Donors

Specificity StudyTotal Specificity Leishmania visceral (sourced from India) 30100% Leishmania cutaneous (sourced from India) 11100% Malaria10100% Cross Reactivity with other Parasitic Infections

PRISM Chagas Assay Sensitivity Chagas Positive Specimens (confirmed by RIPA) RIPA Positive RIPA Negative PRISM Positive PRISM Negative00 Sensitivity 100% Sensitivity

Chagas Confirmatory Assay

Design of Chagas Confirmatory Immunostrip Anti-hIgG (Sample Addition CTL) hIgG-H CTL hIgG-L CTL (Cut-off) 4 rAgs for anti-T. cruzi detection TcF FP3 FP6 FP10 ID# Test BandsOn-board CTL bands

Visual Reading of Test Bands IntensityScore Absent - Faint or < on-board hIgG-L CTL +/- = on-board hIgG-L CTL 1+ Between on-board hIgG-L CTL and hIgG-H CTL 2+ = on-board hIgG-H CTL 3+ > on-board hIgG-H CTL 4+

Sensitivity RIPA Positive RIPA Negative Immunoblot Chagas Confirmatory Positive 410*0 Immunoblot Chagas Confirmatory Negative % Sensitivity * Also reactive in PRISM Assay & 2 reference ELISA’s

Country of Origin# of Samples Argentina 41 Bolivia53 Brazil176 Chile5 Colombia1 Ecuador1 El Salvador12 Honduras4 Mexico33 Nicaragua17 Surinam1 USA4 Venezuela21 Unknown41 Chagas Specimens Panel n = 410 (All are confirmed RIPA positive)

Specificity RIPA Positive PRISM Chagas Assay Non-reactive Immunoblot Chagas Confirmatory Positive 1*0 Immunoblot Chagas Confirmatory Negative % Resolved Specificity Unscreened Random Blood Donors * Also reactive in PRISM Assay & 2 reference ELISA’s

Specificity RIPA Positive PRISM Chagas Assay Non-reactive Immunoblot Chagas Confirmatory Positive 2*0 Immunoblot Chagas Confirmatory Negative % Resolved Specificity Unrelated Medical Conditions * Also reactive in PRISM Assay & 2 reference ELISA’s

Specificity StudyTotal Specificity Leishmania visceral (sourced from India) 30100% Leishmania cutaneous (sourced from India) 11100% Malaria10100% Cross Reactivity with other Parasitic Infections

Summary A fully automated blood screening assay for antibodies to T. Cruzi, on the PRISM system, is under development; Along with an Immunoblot Confirmatory assay, that can be performed on site, to confirm Repeat Reactive specimens to aid in donor management.